M C Weinstein

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability
    April D Kimmel
    Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Cost Eff Resour Alloc 10:12. 2012
  2. pmc Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States
    Lisa J McGarry
    OptumInsight, One Main Street, Suite 1040, Cambridge, MA 02142, USA
    BMC Infect Dis 13:229. 2013
  3. pmc Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
    David R Strutton
    Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL D4555, Collegeville, PA 19426 3930, USA
    BMC Infect Dis 12:175. 2012
  4. pmc Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women
    Jennifer Prah Ruger
    Yale University Schools of Medicine and Public Health, New Haven, CT, USA
    BMC Pregnancy Childbirth 9:46. 2009
  5. pmc Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Jaime L Rubin
    i3 Innovus, 10 Cabot Road, Suite 304, Medford, MA 02155, USA
    BMC Infect Dis 10:14. 2010
  6. ncbi request reprint Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies
    Milton C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 6:9-17. 2003
  7. ncbi request reprint Modeling for health care and other policy decisions: uses, roles, and validity
    M C Weinstein
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Value Health 4:348-61. 2001
  8. ncbi request reprint Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Neurology 52:1138-45. 1999
  9. pmc Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults
    B R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass, USA
    Am J Public Health 91:1456-63. 2001
  10. ncbi request reprint Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Med Care 37:27-32. 1999

Research Grants

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. pmc Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability
    April D Kimmel
    Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Cost Eff Resour Alloc 10:12. 2012
    ..abstract:..
  2. pmc Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States
    Lisa J McGarry
    OptumInsight, One Main Street, Suite 1040, Cambridge, MA 02142, USA
    BMC Infect Dis 13:229. 2013
    ....
  3. pmc Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
    David R Strutton
    Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL D4555, Collegeville, PA 19426 3930, USA
    BMC Infect Dis 12:175. 2012
    ..Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%...
  4. pmc Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women
    Jennifer Prah Ruger
    Yale University Schools of Medicine and Public Health, New Haven, CT, USA
    BMC Pregnancy Childbirth 9:46. 2009
    ..Estimating the costs of outreach programs is critical for understanding the economics of reaching underserved and hard-to-reach populations...
  5. pmc Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Jaime L Rubin
    i3 Innovus, 10 Cabot Road, Suite 304, Medford, MA 02155, USA
    BMC Infect Dis 10:14. 2010
    ..The 2009 novel influenza A (H1N1) outbreak highlights the importance of interventions that may mitigate the impact of a pandemic...
  6. ncbi request reprint Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies
    Milton C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 6:9-17. 2003
    ..This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies...
  7. ncbi request reprint Modeling for health care and other policy decisions: uses, roles, and validity
    M C Weinstein
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Value Health 4:348-61. 2001
    ..Implications for the implementation of Section 114 of the Food and Drug Administration Modernization Act (FDAMA) are derived from this framework...
  8. ncbi request reprint Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Neurology 52:1138-45. 1999
    ..To demonstrate the use of cost-effectiveness analysis to assess the economic impact of donepezil in the treatment of mild or moderate AD...
  9. pmc Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults
    B R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass, USA
    Am J Public Health 91:1456-63. 2001
    ..This study was designed to examine the societal cost-effectiveness and the impact on government payers of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults...
  10. ncbi request reprint Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Med Care 37:27-32. 1999
    ....
  11. ncbi request reprint The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men
    S J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass 02115 5924, USA
    JAMA 281:1822-9. 1999
    ..Homosexual and bisexual men infected with human immunodeficiency virus (HIV) are at increased risk for human papillomavirus-related anal neoplasia and anal squamous cell carcinoma (SCC)...
  12. ncbi request reprint The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women
    S J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard University School of Public Health, Boston, Massachusetts 02115 5924, USA
    Ann Intern Med 130:97-107. 1999
    ..Women with HIV infection have a higher risk for cervical squamous intraepithelial lesions than do women without HIV infection, and the optimal regimen for cervical cancer screening in these women is uncertain...
  13. pmc When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
    ..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
  14. ncbi request reprint Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, MA 02115, USA
    Psychiatr Serv 48:1440-4. 1997
    ....
  15. ncbi request reprint Preference-based measures in economic evaluation in health care
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Annu Rev Public Health 21:587-611. 2000
    ..Widespread acceptance of the methodology likely awaits more consensus on measurement techniques, as well as educational efforts in the public health and medical communities on the usefulness of the approach...
  16. ncbi request reprint Who gets chemotherapy for metastatic lung cancer?
    C C Earle
    Center for Outcomes and Policy Research, Department of Adult Oncology Dana Farber Cancer Institute, Boston, MA 02115, USA
    Chest 117:1239-46. 2000
    ..To determine the prevalence and factors associated with chemotherapy use in elderly patients presenting with advanced lung cancer...
  17. pmc Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA, USA
    AIDS 21:S117-28. 2007
    ..India has more than 5.7 million people infected with human immunodeficiency virus (HIV). In 2004, the Indian government began providing antiretroviral therapy (ART), and there are now an estimated 56 500 people receiving ART...
  18. ncbi request reprint Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults
    Bruce R Schackman
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Arch Intern Med 162:2478-86. 2002
    ....
  19. ncbi request reprint Cost-effectiveness of routine coronary angiography after acute myocardial infarction
    K M Kuntz
    Section for Clinical Epidemiology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 94:957-65. 1996
    ..Coronary angiography is indicated for many patients after acute myocardial infarction (AMI). There are a number of subgroups of AMI patients, however, for whom the indication for coronary angiography is not well established...
  20. ncbi request reprint Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness
    M C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115-5924, USA
    Ann Intern Med 134:440-50. 2001
    ..Primary resistance testing also seems to be reasonably cost-effective and will become more so as the prevalence of primary resistance increases...
  21. ncbi request reprint Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients
    April D Kimmel
    Division of General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Antivir Ther 10:41-52. 2005
    ..Guidelines regarding the frequency of CD4 cell count and HIV RNA monitoring in HIV-infected patients vary, with recommended strategies ranging from every 2 to every 6 months...
  22. ncbi request reprint Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS
    Bruce R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Med Decis Making 22:27-38. 2002
    ....
  23. ncbi request reprint Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines
    Sue J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115 5924, USA
    Arch Intern Med 162:921-8. 2002
    ....
  24. pmc HIV drug resistance surveillance for prioritizing treatment in resource-limited settings
    Rochelle P Walensky
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 21:973-82. 2007
    ..Sentinel testing programs for HIV drug resistance in resource-limited settings can inform policy on antiretroviral therapy (ART) and drug sequencing...
  25. ncbi request reprint The cost-effectiveness of air bags by seating position
    J D Graham
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    JAMA 278:1418-25. 1997
    ..Motor vehicle crashes continue to cause significant mortality and morbidity in the United States. Installation of air bags in new passenger vehicles is a major initiative in the field of injury prevention...
  26. ncbi request reprint A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Decis Making 20:413-22. 2000
    ..The authors compared HUI2 and HUI3 scores of patients with Alzheimer's disease (AD) and caregivers, and contrasted results of a cost-effectiveness analysis of new drugs for AD using the two systems...
  27. pmc Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model
    M C Weinstein
    Institute for Health Research, Harvard School of Public Health, Boston, MA 02115
    Am J Public Health 77:1417-26. 1987
    ..The specific forecasts could be inaccurate, however, as a consequence of erroneous assumptions or misestimated baseline data, and the model awaits validation based on actual future data...
  28. ncbi request reprint Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire
    E Losina
    Departments of Biostatistics and Epidemiology, School of Public Health, Boston University, Boston, MA, USA
    S Afr Med J 96:526-9. 2006
    ..To estimate incidence rates of opportunistic diseases (ODs) and mortality for patients with and without a history of OD among HIV-infected patients in Côte d'Ivoire...
  29. ncbi request reprint Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction
    K M Kuntz
    Program on the Economic Evaluation of Medical Technology, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass 02115 5924, USA
    JAMA 282:2246-51. 1999
    ..Expert panels and decision-analytic techniques are increasingly used to determine the appropriateness of medical interventions, but these 2 approaches use different methods to process evidence...
  30. ncbi request reprint Evaluating the cost-effectiveness of clinical and public health measures
    J D Graham
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115 5924, USA
    Annu Rev Public Health 19:125-52. 1998
    ..Greater uniformity of analytical practice will be necessary if cost-effectiveness analysis is to become a more influential tool in debates about resource allocation...
  31. ncbi request reprint Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus
    S J Goldie
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115-5924, USA
    Am J Med 111:140-9. 2001
    ....
  32. ncbi request reprint The impact of risk information on patients' willingness to pay for autologous blood donation
    S J Lee
    Division of Hematology Oncology, Brigham and Women s Hospital, Boston, MA, USA
    Med Care 36:1162-73. 1998
    ....
  33. ncbi request reprint Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients
    E F Halpern
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Med Decis Making 20:314-22. 2000
    ..As a result, it may lead to premature or incorrect conclusions of superiority. It may also result in inappropriate estimates of the value of further research to inform parameter values...
  34. doi request reprint Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction
    Joseph A Ladapo
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Arch Intern Med 171:39-45. 2011
    ..Supportive contact after discharge improves quit rates but is rarely used...
  35. pmc Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis
    Thomas A Gaziano
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Lancet 368:679-86. 2006
    ..We therefore aimed to establish whether use of evidence-based multidrug regimens for patients at high risk for cardiovascular disease would be cost-effective in low-income and middle-income countries...
  36. ncbi request reprint Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Infect Dis 41:1316-23. 2005
    ..Our objective was to determine the clinical impact and cost-effectiveness of genotype resistance testing for treatment-naive patients with chronic HIV infection...
  37. pmc Cost-effectiveness of treating multidrug-resistant tuberculosis
    Stephen C Resch
    Department of Health Policy and Management, Harvard School of Public Health, Harvard University, Boston, Massachusetts, United States of America
    PLoS Med 3:e241. 2006
    ..We projected the health benefits and cost-effectiveness of using drug susceptibility testing and second-line drugs in a lower-middle-income setting with high levels of MDR TB...
  38. ncbi request reprint Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Prev Med 30:498-506. 2006
    ....
  39. ncbi request reprint Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infants
    John A F Zupancic
    Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Early Hum Dev 82:97-103. 2006
    ..To determine the incremental cost-effectiveness of indomethacin prophylaxis in extremely low birth weight infants enrolled in the Trial of Indomethacin Prophylaxis in Preterms (TIPP)...
  40. ncbi request reprint Do drug formulary policies reflect evidence of value?
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 12:30-6. 2006
    ..To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs)...
  41. ncbi request reprint Medicare and cost-effectiveness analysis
    Peter J Neumann
    Department of Health Policy and Management and the Center for Risk Analysis, Harvard School of Public Health, Boston, USA
    N Engl J Med 353:1516-22. 2005
  42. ncbi request reprint Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  43. ncbi request reprint Recent developments in decision-analytic modelling for economic evaluation
    Milton C Weinstein
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Pharmacoeconomics 24:1043-53. 2006
    ....
  44. pmc Packaging health services when resources are limited: the example of a cervical cancer screening visit
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 3:e434. 2006
    ....
  45. doi request reprint Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain
    Joseph A Ladapo
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:2409-22. 2009
    ....
  46. doi request reprint Adoption and spread of new imaging technology: a case study
    Joseph A Ladapo
    Department of Medicine at Beth Israel Deaconess Medical Center in Boston, Massachusetts, USA
    Health Aff (Millwood) 28:w1122-32. 2009
    ..Further, adoption motivated by operating margins reinforces concerns about haphazard technology acquisition...
  47. doi request reprint Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis
    Janie M Lee
    Department of Radiology, Institute for Technology Assessment, Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 246:763-71. 2008
    ..To project intermediate and long-term clinical outcomes of magnetic resonance (MR) imaging screening for breast cancer in women with BRCA1 gene mutations...
  48. ncbi request reprint Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Paul E Sax
    Division of Infectious Disease and the Partners AIDS Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 39:69-77. 2005
    ..Because of the high cost of ENF compared with other antiretroviral agents, our objectives were to determine the potential long-term clinical impact and cost-effectiveness of ENF in these patients...
  49. doi request reprint Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 248:278-87. 2008
    ....
  50. ncbi request reprint Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis
    Bas Groot Koerkamp
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Med Decis Making 27:101-11. 2007
    ..Presenting the value of information in addition to these intervals allows policy makers to evaluate the need for more empirical research...
  51. pmc The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men
    Alethea W McCormick
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Clin Infect Dis 44:1115-22. 2007
    ..However, the potential reduction in secondary transmission associated with ART may be offset by the longer duration of infectiousness...
  52. ncbi request reprint Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Diseases and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 43:S113-8. 2006
    ..Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds...
  53. ncbi request reprint Can we better prioritize resources for cost-utility research?
    Peter J Neumann
    Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 25:429-36. 2005
    ....
  54. ncbi request reprint Impact of referral patterns on the use of chemotherapy for lung cancer
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, Boston, MA 02115, USA
    J Clin Oncol 20:1786-92. 2002
    ..To determine the extent to which unexplained variation in the use of chemotherapy for advanced lung cancer is due to access to oncologists' services as opposed to treatment decisions made after seeing an oncologist...
  55. ncbi request reprint Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115 5924, USA
    J Natl Cancer Inst 96:604-15. 2004
    ..We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 vaccine in a population with an organized cervical cancer screening program...
  56. ncbi request reprint The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School, 133 Brookline Ave, 6th Floor, Boston, MA 02215, USA
    Med Decis Making 22:506-13. 2002
    ....
  57. ncbi request reprint Long-term persistence in use of statin therapy in elderly patients
    Joshua S Benner
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Suite 341, Boston, MA 02115, USA
    JAMA 288:455-61. 2002
    ....
  58. ncbi request reprint When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Richard H Chapman
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Health Econ 13:429-36. 2004
    ....
  59. ncbi request reprint A therapeutic HIV vaccine: how good is good enough?
    Rochelle P Walensky
    Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, MA 02114, USA
    Vaccine 22:4044-53. 2004
    ..91 months (cost-effectiveness ratio US$ 45,500/QALY). Even modestly effective therapeutic HIV vaccines may produce small but meaningful increases in life expectancy and compare favorably to alternative uses of scarce HIV care resources...
  60. ncbi request reprint Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Value Health 7:554-68. 2004
    ..To perform a cost-effectiveness analysis of three immunomodulatory treatments for newly diagnosed nonprimary progressive MS: interferon beta-1a, interferon beta-1b, and glatiramer acetate...
  61. ncbi request reprint Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
    Sue J Goldie
    Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Am J Med 115:632-41. 2003
    ..To explore the cost-effectiveness of interventions to improve adherence to combination antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection...
  62. pmc Taking account of future technology in cost effectiveness analysis
    Joshua A Salomon
    Department of Population and International Health, Harvard School of Public Health, Harvard Center for Population and Development Studies, 9 Bow Street, Cambridge MA 02138, USA
    BMJ 329:733-6. 2004
  63. ncbi request reprint Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection
    G Scott Gazelle
    Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Zero Emerson Place, Suite 2H, Boston, MA 02114, USA
    Radiology 233:729-39. 2004
    ....
  64. ncbi request reprint Health economic evaluations: the special case of end-stage renal disease treatment
    Wolfgang C Winkelmayer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Med Decis Making 22:417-30. 2002
    ..Uses of the cost-effectiveness ratio of $55,000/LY for center hemodialysis as a lower boundary of society's willingness to pay for an additional life-year can be supported under certain assumptions...
  65. ncbi request reprint Emerging issues in vaccine economics: perspectives from the USA
    Tracy A Lieu
    Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA 02215, USA
    Expert Rev Vaccines 1:433-42. 2002
    ..To optimize the usefulness of vaccine economics research, conceptual issues, such as how to set values for the prevention of illness and how to maximize social equity through investments in vaccines, must be addressed...
  66. ncbi request reprint Daily cost prediction model in neonatal intensive care
    John A F Zupancic
    Department of Neonatology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02458, USA
    Int J Technol Assess Health Care 19:330-8. 2003
    ..To reduce this data collection burden, we identified the key resource items that predict daily ancillary costs for extremely low birth weight infants...
  67. ncbi request reprint Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
    Joshua A Salomon
    Harvard Center for Population and Development Studies, Cambridge, Mass 02138, USA
    JAMA 290:228-37. 2003
    ..Approximately 2.7 million US individuals are chronically infected with the hepatitis C virus (HCV). As public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage...
  68. ncbi request reprint The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis
    Anushua Sinha
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Vaccine 23:3187-95. 2005
    ..Maternal GBS vaccination is predicted to prevent more cases of neonatal GBS disease than current practice and would prevent approximately one in 25 very preterm births...
  69. ncbi request reprint Patient and community preferences for treatments and health states in multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Mult Scler 9:311-9. 2003
    ..To examine preferences for treatments and health states for patients with relapsing-remitting MS and members of the community...
  70. ncbi request reprint Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity
    John A F Zupancic
    Department of Neonatology, Beth Israel Deaconess Medical School, Boston, Massachusetts 02215, USA
    Pediatrics 111:146-52. 2003
    ..Our objective was to establish the economic impact of varying durations of predischarge observation for apnea of prematurity...
  71. ncbi request reprint Whose blood is safer? The effect of the stage of the epidemic on screening for HIV
    E Litvak
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 17:455-63. 1997
    ..With improvements in HIV antibody test (ELISA) performance, the window of time between infection and seroconversion becomes a major source of error in HIV screening. The authors examined its impact on the false-reassurance rate (FRR)...
  72. ncbi request reprint Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy
    Rochelle P Walensky
    Division of Infectious Disease and the Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Acquir Immune Defic Syndr 31:27-37. 2002
    ..These results can assist decision makers and those planning clinical trials in defining evidence-based performance measures for primary HIV infection treatment and future trials...
  73. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  74. ncbi request reprint Routine human immunodeficiency virus testing: an economic evaluation of current guidelines
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Med 118:292-300. 2005
    ..Our objective was to evaluate the clinical effect and cost-effectiveness of current guidelines and of alternate HIV prevalence thresholds...
  75. pmc Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:392-400. 2010
    ..We forecast outcomes of this approach if implemented in Washington DC...
  76. ncbi request reprint The cost effectiveness of gonorrhea screening in urban emergency departments
    Julia E Aledort
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Sex Transm Dis 32:425-36. 2005
    ..The prevalence of gonorrhea (GC) among adolescent and young women attending some urban emergency departments (EDs) ranges from 1% to 7%, but historically screening has not been logistically practical...
  77. ncbi request reprint Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis
    C C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1064-70. 2001
    ..To compare the effectiveness of chemotherapy given to elderly patients in routine practice for stage IV non-small-cell lung cancer (NSCLC) with the efficacy observed in randomized trials...
  78. pmc Should physicians be gatekeepers of medical resources?
    M C Weinstein
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, School of Public Health, Harvard University, Boston, Massachusetts, USA
    J Med Ethics 27:268-74. 2001
    ..Such solutions will be politically and ethically sustainable only if patients as citizens of the larger population accept the need for rationing of limited resources in health care...
  79. ncbi request reprint Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level
    Thomas A Gaziano
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 112:3569-76. 2005
    ..Guidelines based on blood pressure level for initiation of treatment of hypertension may be too costly compared with an approach based on absolute cardiovascular disease (CVD) risk, especially in developing countries...
  80. pmc Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period
    Pamela M McMahon
    Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
    Cancer 113:3440-9. 2008
    ..This study estimated changes in lung cancer outcomes through 2005, had chest CT screening been introduced in 1990...
  81. ncbi request reprint Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods
    Bas Groot Koerkamp
    Department of Health Policy and Management, Harvard School of Public Health, Harvard Center for Risk Analysis, Boston, MA, USA
    Health Econ 15:383-92. 2006
    ..The objective of this paper is to set out the correct methods to estimate the partial expected value of perfect information and to demonstrate why the generally recommended method is incorrect conceptually and mathematically...
  82. ncbi request reprint Medical management of gallstones: a cost-effectiveness analysis
    M C Weinstein
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115
    J Gen Intern Med 5:277-84. 1990
    ..CONCLUSION: Ursodiol is a clinically advantageous and cost-effective alternative to elective cholecystectomy, especially for older and high-risk patients...
  83. ncbi request reprint The costs of prevention
    M C Weinstein
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115
    J Gen Intern Med 5:S89-92. 1990
    ..Another lesson is that prevention programs should not be subjected to a higher standard than other health programs: they should not be expected to save money, but they should be expected to yield improved health at a reasonable price...
  84. doi request reprint The global cost of nonoptimal blood pressure
    Thomas A Gaziano
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Hypertens 27:1472-7. 2009
    ..However, no exhaustive study has been done to evaluate its potential costs, globally. We, therefore, set out to estimate the global economic cost of nonoptimal blood pressure...
  85. pmc Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis
    G Scott Gazelle
    Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Zero Emerson Place, Suite 2H, Boston, MA 02114, USA
    Ann Surg 237:544-55. 2003
    ....
  86. ncbi request reprint Does preventive care save money? Health economics and the presidential candidates
    Joshua T Cohen
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, USA
    N Engl J Med 358:661-3. 2008
  87. doi request reprint Heart failure disease management programs: a cost-effectiveness analysis
    David C Chan
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:332-8. 2008
    ..Current guidelines thus only recommend disease management targeted to high-risk patients with HF...
  88. pmc Cost-effectiveness of HIV testing and treatment in the United States
    Rochelle P Walensky
    Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 45:S248-54. 2007
    ..This article reviews the methods and results of cost-effectiveness studies in the United States and articulates why routine, voluntary HIV testing is not only of crucial public health importance but also economically justified...
  89. ncbi request reprint Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
    Med Decis Making 26:497-511. 2006
    ..This approach is suggested when modeling a disease that causes a large proportion of all-cause mortality, particularly when mortality from the disease of interest and other-cause mortality are both affected by the same risk factor...
  90. pmc Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity
    Andrea L Ciaranello
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 22:2359-69. 2008
    ..We sought to identify the currently recommended regimen to prevent mother-to-child transmission that optimally balances risks of pediatric HIV infection and neurologic mitochondrial toxicity...
  91. ncbi request reprint Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Med Decis Making 25:321-9. 2005
    ..Using the example of HIV testing, the authors explore the optimal targeting of funds within this pathway...
  92. ncbi request reprint Empirically calibrated model of hepatitis C virus infection in the United States
    Joshua A Salomon
    Global Programme on Evidence for Health Policy, World Health Organization, Geneva, Switzerland
    Am J Epidemiol 156:761-73. 2002
    ..These findings have important implications both for individual clinical decisions and for broader public health policy...
  93. ncbi request reprint The survival benefits of AIDS treatment in the United States
    Rochelle P Walensky
    Division of Infectious Disease and General Medicine, Massachusetts General Hospital, Boston 02114, USA
    J Infect Dis 194:11-9. 2006
    ..As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States...
  94. ncbi request reprint Expanded screening for HIV in the United States--an analysis of cost-effectiveness
    A David Paltiel
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Conn 06520 8034, USA
    N Engl J Med 352:586-95. 2005
    ..The effect of expanded screening for HIV is unknown in the era of effective antiretroviral therapy...
  95. ncbi request reprint Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs
    Elena B Elkin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 44, New York, NY 10021, USA
    Breast Cancer Res Treat 93:25-34. 2005
    ..We used a decision-analytic framework to evaluate tradeoffs between efficacy and quality of life in the choice between these treatments...
  96. ncbi request reprint Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes
    Allison B Rosen
    Division of General Medicine, University of Michigan Health Systems, 300 North Ingalls, Suite 7E10, Ann Arbor, MI 48109, USA
    Ann Intern Med 143:89-99. 2005
    ..Angiotensin-converting enzyme (ACE) inhibitors slow renal disease progression and reduce cardiac morbidity and mortality in patients with diabetes. Patients' out-of-pocket costs pose a barrier to using this effective therapy...
  97. ncbi request reprint The lifetime cost of current human immunodeficiency virus care in the United States
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, New York 10021, USA
    Med Care 44:990-7. 2006
    ..We sought to project the lifetime cost of medical care for human immunodefiency virus (HIV)-infected adults using current antiretroviral therapy (ART) standards...
  98. ncbi request reprint HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis
    Elena B Elkin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
    J Clin Oncol 22:854-63. 2004
    ..Several tests of varying accuracy and cost are available to identify candidates for trastuzumab. We estimated the cost-effectiveness of alternative HER-2 testing and trastuzumab treatment strategies...
  99. ncbi request reprint Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs
    A David Paltiel
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut 06520 8034, USA
    Ann Intern Med 145:797-806. 2006
    ..An extensive literature supports expanded HIV screening in the United States. However, the question of whom to test and how frequently remains controversial...
  100. ncbi request reprint Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment
    Bruce R Schackman
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Health Care Financ Rev 26:67-80. 2005
    ....
  101. ncbi request reprint Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    Antivir Ther 7:257-66. 2002
    ..To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART)...

Research Grants2

  1. Harvard University Health Services Research Training Gr*
    Milton Weinstein; Fiscal Year: 2007
    ..This proposal will allow the next generation of these investigators to continue to address evolving issues in health services research. ..